Burning Rock Biotech (BNR) Expected to Announce Earnings on Tuesday

Key Points

• Q4 2025 earnings are expected before the market opens on March 31, with analysts forecasting an EPS loss of ($2.2875) and revenue of $19.20 million.
• Latest reported quarter showed an EPS of ($0.21) on $18.05 million in revenue, and the company has negative financial metrics (ROE ≈ -9.98%, net margin ≈ -10.27%) while the stock recently traded down about 11.6% and has a market cap of $176.03 million.
• About 30% of shares are held by institutions; Marshall Wace initiated a small stake, and analysts' consensus is an average rating of "Sell" despite a recent upgrade from one firm to "Buy."

Burning Rock Biotech (NASDAQ:BNR - Get Free Report) is expected to announce its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($2.2875) per share and revenue of $19.20 million for the quarter. Parties can find conference call details on the company's upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 12, 2026 at 7:00 AM ET.

Burning Rock Biotech (NASDAQ:BNR - Get Free Report) last issued its earnings results on Saturday, February 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. The business had revenue of $18.05 million during the quarter. Burning Rock Biotech had a negative return on equity of 9.98% and a negative net margin of 10.27%.

Burning Rock Biotech Trading Down 11.6%

NASDAQ:BNR opened at $16.36 on Friday. The stock has a 50 day moving average of $27.03 and a 200-day moving average of $19.25. The firm has a market capitalization of $176.03 million, a PE ratio of -20.71 and a beta of 1.35. Burning Rock Biotech has a 52 week low of $2.18 and a 52 week high of $41.72.

Hedge Funds Weigh In On Burning Rock Biotech

An institutional investor recently bought a new position in Burning Rock Biotech stock. Marshall Wace LLP bought a new stake in shares of Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 10,903 shares of the company's stock, valued at approximately $220,000. Marshall Wace LLP owned approximately 0.10% of Burning Rock Biotech at the end of the most recent reporting period. 30.03% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Wall Street Zen upgraded Burning Rock Biotech from a "hold" rating to a "buy" rating in a research report on Saturday, January 17th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Burning Rock Biotech in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of "Sell".

About Burning Rock Biotech

Burning Rock Biotech NASDAQ: BNR is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company's core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.